Ipca Labs

Top trading ideas: Aakash Shah of Choice Equity Broking suggests buying these three stocks today; here's why

Emkay Global initiated coverage of Ipca Labs shares with 'Buy' rating and a share price target of ₹1,700 -- a 19 per cent upside from current levels

Ipca Laboratories share price was trading 6.2 per cent higher at ₹1,382.60 compared to previous session's close of ₹1,302 on the NSE

Among stocks, Natco Pharma plunged 37.85%, Ipca Labs 22.43%, Aurobindo Pharma 17.99%, and Sun Pharma 14.30%. Other laggards include Lupin (13.25%), and Dr Reddy's (5.17%).

Nifty Pharma index declined 1.5 per cent in trade after US President Donald Trump warned to impose a 25 per cent tariff on Indian goods starting August 1

Aurobindo Pharma, IPCA Labs, Oil India, Mazagon Dock and GIC RE are the 5 midcap stocks that can potentially surge up to 24% from present levels, suggests technical charts.

Shares of IPCA Laboratories have yielded a return of 8 per cent in the last six months and nearly 30 per cent in the last one year for its investors

Q3FY25 company results, February 13: United Breweries, Ipca, and SVJN will be among 389 firms releasing their earnings report for the Oct-Dec 2024 quarter

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

The daily chart indicates a multiple-pattern bullish breakout for Mangalam Cement

As per BSE bulk deal data, the company's promoter Usha M Chandurkar sold 40,00,000 lakh shares for Rs 1,501.52 per share, reducing her holding from 3.27 per cent as of September-end

Ipca Laboratories on Thursday said its consolidated net profit declined 58 per cent year-on-year to Rs 229 crore in the September quarter. The drug firm had reported a net profit of Rs 145 crore in the year-ago period. Revenue from operations rose to Rs 2,355 crore for the second quarter of the current fiscal year as compared with Rs 2,034 crore in the year-ago period, Ipca Laboratories said in a regulatory filing. The company said its domestic formulations business revenue stood at Rs 940 crore for the quarter, up 11 per cent from Rs 845 crore a year earlier. Export of generics stood at Rs 286 crore in the July-September period as against Rs 264 crore, registering a year-on-year growth of 8 per cent. The company said its board has approved an interim dividend of Rs 21 per share of Re 1 each for 2024-25. Shares of the company on Thursday ended 2.02 per cent up at Rs 1,538.65 apiece on the BSE.

Unichem Labs share price: Unichem Laboratories' board has approved asset purchase agreement with Bayshore Pharmaceuticals

Ipca laboratories share price surged up to 3.66 per cent intraday, hitting their all time high at Rs 1509.45 per share on the BSE

This drug has shown a 77.20 per cent ulcer closure rate in clinical trials, offering hope for a condition that often leads to severe outcomes like lower limb amputations

Shares of Ipca Labs slipped 2.82 per cent to Rs 1312.55 per share on the BSE in Friday's early morning trade

Ipca Laboratories on Tuesday said its consolidated net profit increased 18 per cent to Rs 192 crore for the first quarter ended June 30, 2024 aided by robust sales in the domestic market. The drug firm had reported a net profit of Rs 163 crore for the April-June period of last fiscal. Revenue from operations rose to Rs 2,093 crore for the April-June quarter, as compared to Rs 1,585 crore in the year-ago period, Ipca Laboratories said in a regulatory filing. The drug firm said domestic formulations income rose 12 per cent year-on-year to Rs 873 crore in the first quarter. Exports income, however, declined 4 per cent year-on-year to Rs 591 crore during the June quarter, the company said. Shares of Ipca Laboratories on Tuesday closed 1.33 per cent up at Rs 1,400 apiece on the BSE.

Hindustan Unilever is in overall uptrend and is on the verge of giving Pole and Flag pattern breakout on daily chart

The uptick in share price came after the company announced that the EU Court upheld Rs 126 crore fine imposed on Ipca Labs' unit, Unichem Laboratories

Ipca Laboratories on Wednesday reported 67 per cent increase in consolidated net profit at Rs 180 crore for the third quarter ended December 31, 2023. The drugmaker had reported a net profit of Rs 108 crore for October-December FY23. Revenue from operations rose to Rs 2,053 crore from Rs 1,546 crore in the year-ago period, Ipca Laboratories said in a regulatory filing. Shares of the company were trading 0.86 per cent down at Rs 1,150.15 apiece on the BSE.